

QIBA PET-Amyloid Biomarker Committee

Friday, July 9, 2021, at 9 AM CT

Call Summary

Primary notes provided by Dr. Smith

In attendance:

Anne Smith, PhD (Co-chair)

Tammie Benzinger, MD, PhD

Rachid Fahmi, MSc, PhD

Norman Foster, MD

Adriaan Lammertsma, PhD

Nancy Obuchowski, PhD

Jean-Luc Vanderheyden, PhD

Dean F. Wong MD, PhD

RSNA

Joe Koudelik

Julie Lisiecki

Notes from Moderator: Dr. Smith

1. Submit to the larger QIBA organization the Profile for vote on Technical Confirmation
 - Outstanding issues
 - i. Changes to DICOM tags (e.g., clarify series names) for the PET Amyloid Digital Reference Object (DRO)
 - ii. Inclusion of the T1-weighted MRI with the simulated PET amyloid burden DRO images (permission has been received to use the original image from the University of Washington)
 - iii. Minor requested edits to the Profile text (in particular, incorporate feedback from the DRO)
 - Submit for publication the attached manuscript
 - i. Plan is to submit to the [Alzheimer's and Dementia](#) Journal
 - Chosen based on high impact factor
 - Please send suggestions to the co-chairs: anne.m.smith@siemens-healthineers.com; dmatthews@admdx.com; sminoshima@hsc.utah.edu
 - ii. Any feedback/edits would be greatly appreciated
 - Language being considered for addition regarding the FDA approval of Aduhelm (aducanumab) to the manuscript and the Profile
 - iii. Dr. Adriaan Lammertsma is going to give feedback for how standardized PET Amyloid imaging may be done differently in Europe
 - Engage with SNMMI and any organization who believe that the use of PET Amyloid imaging can improve the use and follow-up of Biogen's newly FDA-approved Alzheimer's treatment Aduhelm
 - i. Dr. Smith copies Dr. Alex Guimaraes, the head of QIBA, to keep him informed of these high-level engagements

Additional notes

- Dr. Wong offered to speak with members of the SNMMI Brain Imaging Council to discourage a duplicate publication
- Dr. Foster encouraged the group to also investigate immunotherapies as clinical trials are using PET amyloid in innovative and quantitative ways
- Dr. Foster will add some additional detail to the manuscript to strengthen the case for why PET amyloid is a better choice than blood-based biomarkers and Cerebrospinal fluid (CSF) amyloid biomarkers
- It was noted that PET amyloid may be used for diagnosis, patient selection, and to assess treatment efficacy
- For future discussion: the ethics of using research results as a potential patient recruitment tool

Action items (ongoing) – aim to complete by August call

- Dr. Smith or Ms. Matthews to add a Profile note indicating that data are simulated for HIPAA regulations
- Dr. Vanderheyden to contact United Imaging colleagues to evaluate DRO and inquire about the manuscript
- Dr. Lammertsma to add European differences and contact Australian colleagues: [Christopher Rowe, MD](#), and [Victor Villemagne, MD](#), as well as [Simon Cherry, PhD](#)
- Dr. Minoshima to ask Japanese colleagues to read manuscript and point out any Japanese differences
- Dr. Sunderland to contact Korean colleagues to read manuscript and note and differences
- Ms. Matthews to reformat the Profile checklist from Excel to Word for ease of use
- Co-chairs to finalize feasibility questionnaire and discuss Mr. O'Donnell's suggestions

Next calls – August 13th at 9 am CT (PET Amyloid BC); August 20th at 9 am CT (Nuclear Medicine CC)